Company news
Cipher Pharmaceuticals Inc. news in 2018
Cipher Pharmaceuticals Inc.'s news releases, calls and decks from 2018, newest first.
Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
December 18, 2018
Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada
December 17, 2018
Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018
December 5, 2018
Cipher Pharmaceuticals adds new Vice President, Canadian Commercial Operations
December 4, 2018
Cipher Pharmaceuticals Reports Q3 2018 Results
November 7, 2018
Notice of Cipher Pharmaceuticals Q3 2018 Conference Call
October 24, 2018
Cipher Pharmaceuticals Announces Canadian Launch of Brinavess® (vernakalant hydrochloride)
October 24, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to MOB-015 from Moberg Pharma for the topical treatment of Onychomycosis
September 18, 2018
Cipher Pharmaceuticals Receives Health Canada Approval of Xydalba(TM) (dalbavancin hydrochloride)
September 10, 2018
Cipher Pharmaceuticals Reports Q2 2018 Results
August 10, 2018
Cipher Pharmaceuticals Announces Amended Distribution and Supply Agreement for Absorica®
July 30, 2018
Notice of Cipher Pharmaceuticals Q2 2018 Conference Call
July 23, 2018
Cipher Pharmaceuticals Adds New Vice President, Scientific & Medical Affairs
June 6, 2018
Cipher Pharmaceuticals Inc. Completes Acquisition of 100% of Cardiome Pharma Corp.
May 16, 2018
Cipher Pharmaceuticals Completes Acquisition of Canadian Business Portfolio of Cardiome Pharma
May 15, 2018
Cipher Pharmaceuticals Reports Q1 2018 Results
May 10, 2018
Notice of Cipher Pharmaceuticals Q1 2018 Conference Call & Annual Meeting
May 1, 2018
Cipher Pharmaceuticals Proposes Adding Dr. Laurence Terrisse-Rulleau To Board of Directors
April 26, 2018
Cipher Pharmaceuticals to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference
April 24, 2018
Cipher Pharmaceuticals Provides Corporate Update and Preliminary Q1 2018 Revenue Results
April 23, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to U.S. FDA-Approved A-101 40% Topical Solution from Aclaris Therapeutics
April 6, 2018
Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome
March 20, 2018
Cipher Pharmaceuticals Reports Q4 & FY2017 Results
February 28, 2018
Cipher Pharmaceuticals Acquires Exclusive Canadian Rights to FDA-Approved TRULANCE® from Synergy Pharmaceuticals
February 28, 2018
Notice of Cipher Pharmaceuticals Q4 and Year-End 2017 Conference Call
February 9, 2018
Cipher Pharmaceuticals and Italmex Pharma Announce Exclusive Distribution Agreement for Isotretinoin Product in Mexico
January 9, 2018
Cipher Pharmaceuticals Announces Canadian Launch of OZANEX(TM) (ozenoxacin cream 1%), a Novel Topical Antibiotic
January 8, 2018